Bacillus coagulans (Weizmannia coagulans)
Bacillus coagulans is a lactic acid-producing bacterium that forms hardy spores. It was once sold as Lactobacillus sporogenes and now also appears as Weizmannia or Heyndrickxia coagulans. The research is strain-specific: the main strains are Unique IS2, MTCC 5856 (sold as LactoSpore) and GBI-30, 6086 (sold as BC30), and results do not carry over between strains. Placebo-controlled trials of Unique IS2 in adults with IBS or infrequent bowel movements, and of GBI-30, 6086 in adults with digestive complaints, report less abdominal pain or more regular stools, but most are small and industry-funded, usually by the maker, and a constipation meta-analysis found no clear effect on stool frequency for pooled Unique IS2 trials. An infant trial of an unnamed strain was null. Small studies report higher blood amino acids when a strain is taken with protein. It is not a treatment for any digestive disease.
Benefits
Abdominal discomfort, bloating and stool form
In adults diagnosed with IBS, strain Unique IS2 (2 billion CFU daily) eased abdominal pain and raised complete bowel movements versus placebo in a maker-funded trial. Strain MTCC 5856 improved bloating, pain and stool frequency in a small pilot in diarrhea-type IBS, but all participants also took prescription drugs, including an antibiotic. A strain-by-strain meta-analysis supported Unique IS2 from two trials, one in children.
After-meal gas and abdominal discomfort in adults without a diagnosis
In 61 adults with after-meal gas but no digestive diagnosis, a capsule combining strain GBI-30, 6086 with a digestive enzyme blend improved abdominal pain and total symptom scores more than placebo over 4 weeks. Bloating showed only a trend, and a strong placebo response left many measures without a difference. Because of the enzymes, the effect cannot be credited to the bacterium alone. The strain's maker funded the trial.
Stool frequency and consistency
Strain Unique IS2 increased bowel movements versus placebo in 100 adults with functional constipation and improved stool consistency, mainly through fewer hard stools, in 144 healthy adults with infrequent bowel movements, without changing overall gut symptoms. Strain GBI-30, 6086 raised weekly stools in 111 healthy adults. A meta-analysis of pooled Unique IS2 trials, however, found no significant rise in stool frequency.
Studied as an add-on to oral rehydration in children
In 110 children aged 1 to 10 with acute diarrhea, strain MTCC 5856 given with oral rehydration and zinc for 5 days shortened diarrhea by about 11 hours versus placebo in a maker-run trial, though daily stool frequency did not differ. An earlier trial in 148 children aged 6 to 24 months using an unnamed strain found no effect. Diarrhea in young children needs medical care.
Amino acid absorption from protein
Taken with a daily protein shake, strain GBI-30, 6086 raised blood amino acid levels after the meal in two small crossover studies of 30 people each (milk protein, and rice and pea protein). Strain Unique IS2 taken with whey for 60 days raised blood amino acids in trained men, and the authors also report gains in leg-press strength. Apart from that strength result, these are blood markers from small, maker-linked studies.
Mechanism of action
Spores that pass the stomach and germinate in the gut
Bacillus coagulans forms tough spores. Maker-linked research on strain GBI-30, 6086 describes the spores surviving stomach acid and germinating in the intestine, where the bacteria become active. How many spores of a given product survive and germinate in people has rarely been measured directly, and it can differ by strain and formulation.
Lactic acid production
Once active, the bacterium ferments sugars into lactic acid. A lower local pH is a proposed way it shifts the gut environment. Trials have measured only small changes in gut bacteria, and one trial found no change in microbiota composition at all.
Help with breaking down dietary protein
Strain GBI-30, 6086 increased protein digestion in a laboratory model of the stomach and small intestine. The proposed idea is that germinated cells release protein-digesting enzymes that free more amino acids for absorption. Higher blood amino acid levels after a protein meal fit this idea, but the enzyme effect itself has not been measured in people.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Bacillus coagulans strain Unique IS2, 2 billion CFU daily for 8 weeks, after a 2-week placebo run-in (Madempudi et al. 2019, Sci Rep).
136 adults aged 18 to 60 meeting Rome III criteria for IBS, randomized after a run-in that excluded non-compliant participants; 108 completed and were analyzed.
Both primary outcomes, abdominal pain intensity and complete spontaneous bowel movements, improved more than with placebo (79% versus 40% reached the bowel movement responder goal), as did secondary symptoms. Blood inflammatory markers did not change. No severe adverse events were reported. Unique Biotech, the strain's maker, fully funded the trial, and three authors are its employees.
Randomized, double-blind, placebo-controlled, three-center pilot of Bacillus coagulans strain MTCC 5856, 2 billion CFU/day for 90 days; both groups also took standard drug care chosen by the investigators: domperidone with esomeprazole, and the antibiotic metronidazole (Majeed et al. 2016, Nutr J).
36 people newly diagnosed with diarrhea-predominant IBS (18 per group).
Bloating, vomiting, diarrhea, abdominal pain and stool frequency improved more than with placebo (p < 0.01), and quality of life rose. Because every participant also took prescription drugs, including an antibiotic, this is a disease-treatment result rather than evidence for healthy digestion. The trial was small and was run by the strain's maker, Sami Labs and Sabinsa.
Randomized, double-blind, placebo-controlled trial of Bacillus coagulans strain Unique IS2, 2 billion CFU/day for 4 weeks after a 2-week run-in (LeMoire et al. 2025, Benef Microbes).
144 healthy adults averaging 3 to fewer than 7 complete bowel movements per week.
The abstract reports a significant rise in bowel movement frequency, the primary outcome (p = 0.037), without stating it as a comparison with placebo. Stool consistency, a secondary outcome, improved more than with placebo (p = 0.018), mainly through fewer hard stools. There was no effect on GI symptoms, quality of life or gut microbiota. PepsiCo sponsored the trial, and three co-authors work there.
Randomized, double-blind, placebo-controlled trial of Bacillus coagulans strain GBI-30, 6086, 1 billion per day for 4 weeks (Gang et al. 2025, Benef Microbes).
111 healthy adults aged 18 to 65 with functional GI complaints that did not meet criteria for a disease.
Stools per week increased (p = 0.036), consistency improved (p < 0.001) and fewer participants had constipation (p < 0.001) versus placebo; these are three of the seven primary outcomes registered on ClinicalTrials.gov, which also include defecation effort and digestive symptom scores that the abstract does not report separately. With seven primary outcomes, the consistency and constipation results would pass a Bonferroni cutoff of about 0.007, but the stool count result would not. Gut bacteria changed only slightly. Kerry, which sells the strain, sponsored the trial, and four of the seven authors work for Kerry companies.
Randomized, double-blind, placebo-controlled trial of strain MTCC 5856 (400 million spores) or placebo with oral rehydration solution and zinc for 5 days (Majeed et al. 2023, Front Pediatr).
110 non-hospitalized children aged 1 to 10 with acute diarrhea of any cause.
Diarrhea lasted 51.3 hours with the probiotic versus 62.7 hours with placebo (p = 0.011), and dehydration status improved more. Daily diarrhea frequency was lower but not significantly. Both groups also received oral rehydration and zinc. Most authors are employees of the maker.
Randomized, double-blind, placebo-controlled hospital trial of Lactobacillus sporogenes (Bacillus coagulans) tablets of unstated strain, given with oral rehydration to children with acute watery diarrhea and some dehydration (Dutta et al. 2011, Trop Med Int Health).
148 hospitalized children aged 6 to 24 months with acute illness and some dehydration (78 given the bacterium, 70 placebo).
Recovery rate, duration, frequency and fluid losses of the illness, and rehydration fluid intake did not differ significantly between groups, including in rotavirus cases. The authors concluded the product had no therapeutic impact. This null result is one reason findings for one strain should not be assumed for another.
Randomized, double-blind crossover with two 14-day supplementation periods separated by a 3-week washout: 20 g rice and pea protein daily with or without 1 billion CFU BC30, with blood sampling for 4 hours after the final dose (Walden et al. 2024, Probiotics Antimicrob Proteins).
30 healthy women, average age 58.5.
Total amino acids, essential amino acids, tryptophan, cysteine and alanine had greater area under the curve with BC30 (p values 0.003 to 0.050). Time to peak was similar. Blood amino acids are a marker, not a muscle or health outcome. Funded by an unrestricted grant from Kerry, which supplied both products.
Double-blind, placebo-controlled trial: 20 g whey protein daily with 2 billion CFU Unique IS-2 or with placebo for 60 days alongside a controlled resistance-training program (Tarik et al. 2022, Eur J Nutr).
Resistance-trained men averaging 21 years old.
Total plasma free amino acids rose 16.1% (p = 0.004), and branched-chain amino acids were 33.1% higher than with placebo at 60 days. The authors also report gains in leg-press 1RM (+16.6%, p = 0.024) and vertical jump power (+7.9%, p = 0.007) among several strength and body measures. One trial, with two co-authors from the strain's maker.
Randomized, double-blind, placebo-controlled trial of Bacillus coagulans strain Unique IS2, 2 billion CFU or placebo once daily for 4 weeks; treatment success was defined as three or more spontaneous stools a week (Madempudi et al. 2020, Probiotics Antimicrob Proteins).
100 adults diagnosed with functional constipation.
By week 4, bowel movements increased more than with placebo (p < 0.001), 98% reached normal stool consistency versus 74% on placebo, and incomplete evacuation, painful defecation and abdominal pain eased more. The abstract does not give the treatment success rate. Authors include employees of the maker, Unique Biotech.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Bacillus coagulans (Weizmannia coagulans)
Why does the strain on the label matter so much?
Probiotic effects are tested strain by strain. Unique IS2, MTCC 5856 (LactoSpore) and GBI-30, 6086 (BC30) are all Bacillus coagulans, but each has its own small set of trials, often on different outcomes. A pooled analysis found benefits for Unique IS2 in IBS, while an infant diarrhea trial of an unnamed strain found none. Look for a product that names its strain and matches the dose used in that strain's trials.
Is it the same as Lactobacillus sporogenes, Weizmannia coagulans or Heyndrickxia coagulans?
Yes, these are names for the same species. Older products and papers call it Lactobacillus sporogenes; it was later classified as Bacillus coagulans. Taxonomists have since moved it to the genus Weizmannia and then proposed folding that genus into Heyndrickxia, so recent papers use all three names.
Can it make bowel movements more regular?
Results differ by strain and study. Strains Unique IS2 and GBI-30, 6086 increased bowel movements or improved stool consistency over 4 weeks in small placebo-controlled trials, but a meta-analysis that pooled the Unique IS2 constipation trials found no significant increase in stool frequency. Persistent constipation, or any sudden change in bowel habits, is worth discussing with a doctor.
Is a heat-killed product such as StaiMune the same as live spores?
No. StaiMune contains inactivated cells of strain GBI-30, 6086, so it cannot germinate or make lactic acid in the gut. The trials on this page used live spores, and their results should not be assumed for an inactivated version, which has its own separate research, starting with laboratory work on immune cells.
What is Bacillus coagulans?
Bacillus coagulans is a lactic acid-producing bacterium that forms hardy spores. It was once sold as Lactobacillus sporogenes and now also appears as Weizmannia or Heyndrickxia coagulans.
What is Bacillus coagulans used for?
NutraSmarts does not list Bacillus coagulans under a health category. What the research covers: In adults diagnosed with IBS, strain Unique IS2 (2 billion CFU daily) eased abdominal pain and raised complete bowel movements versus placebo in a maker-funded trial.
What is the recommended dosage of Bacillus coagulans?
The clinically studied dose is 1 to 2 billion CFU once daily for 4 weeks to 90 days: 2 billion for Unique IS2 and MTCC 5856, 1 billion for GBI-30, 6086. A 5-day children's trial used 400 million spores of MTCC 5856. Use the dose tested for the strain on the label. Always follow the product label and check with a healthcare provider for personal advice.
Is Bacillus coagulans safe, and does it have side effects?
Side effects and cautions reported for Bacillus coagulans include: The cited trials ran from 5 to 90 days. A strain-by-strain IBS meta-analysis found adverse events with Unique IS2 and MTCC 5856 no more frequent than with placebo, and in the children's trial of MTCC 5856 the only adverse events reported were mild stomach irritation, seen in both… It may also interact with some medications. Bacillus coagulans is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.
Does Bacillus coagulans interact with any medications?
Possible interactions include: Antibiotics: no cited trial tested taking this probiotic with an antibiotic or how far apart to space them, so ask a pharmacist about timing. Immunosuppressant medicines (for example after an organ transplant): NCCIH notes a higher risk of harmful effects from probiotics in peopl… If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Bacillus coagulans?
NutraSmarts rates the evidence for Bacillus coagulans as Moderate (3 out of 5). It is backed by 9 study summaries and 18 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(18 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. J Clin Med. 2026;15(3):1152. doi: 10.3390/jcm15031152.PubMedUsed to support: Strain-by-strain meta-analysis of single-strain probiotic trials in IBS (32 articles, 10 strains). Bacillus coagulans Unique IS2 (MTCC 5260), pooled from two trials (one in adults, one in children), reduced abdominal pain, bloating and overall IBS symptoms versus placebo, though variability between the trials was high for several outcomes. For MTCC 5856, only quality of life could be pooled (two trials) and it improved. GBI-30, 6086 could not be analyzed. Adverse events did not differ from placebo for either strain.
- Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Nutrients. 2023;15(17):3856. doi: 10.3390/nu15173856.PubMedUsed to support: Network meta-analysis of 81 probiotic RCTs (9,253 adults with IBS). Bacillus coagulans MTCC 5856 and Unique IS2 ranked among the most effective probiotics for abdominal pain, and MTCC 5856 ranked highly for stool form in diarrhea-type IBS. Rankings compare many products indirectly and the authors call for confirmation.
- Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2022;41(12):2759-2777. doi: 10.1016/j.clnu.2022.10.015.PubMedUsed to support: Meta-analysis of 30 probiotic RCTs in adults with chronic constipation. Probiotics overall raised stool frequency, but the Bacillus coagulans Unique IS2 subgroup did not show a significant effect on stool frequency. The authors flag high heterogeneity and risk of bias.
- Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016;15:21. doi: 10.1186/s12937-016-0140-6.PubMedUsed to support: Randomized, double-blind, placebo-controlled pilot in 36 people newly diagnosed with diarrhea-predominant IBS, given strain MTCC 5856 (2 billion CFU/day) or placebo for 90 days. Both groups also took standard drug care: domperidone with esomeprazole, and the antibiotic metronidazole. Bloating, abdominal pain, diarrhea and stool frequency improved more than with placebo, and quality of life rose. Authors are from Sami Labs and Sabinsa, the strain's maker.
- Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci Rep. 2019;9(1):12210. doi: 10.1038/s41598-019-48554-x.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 136 adults with IBS (Rome III) after a 2-week placebo run-in; 108 completed. Strain Unique IS2 (2 billion CFU daily for 8 weeks) improved abdominal pain intensity and complete spontaneous bowel movements, the two primary outcomes, versus placebo. Blood cytokines did not change. Unique Biotech, the strain's maker, fully funded the trial, and three authors are its employees.
- A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol. 2009;9:85. doi: 10.1186/1471-230X-9-85.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 61 adults with after-meal gas symptoms and no GI diagnosis, given a capsule of strain GBI-30, 6086 (2 billion CFU) plus a digestive enzyme blend (Digestive Advantage Gas Defense Formula) for 4 weeks. The product group improved more on the GSRS abdominal pain subscore (p = 0.046) and total score (p = 0.048); distension showed only a trend (p = 0.061), and a strong placebo effect meant many outcomes did not differ between groups. Funded by Ganeden, then the strain's maker.
- Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study. Probiotics Antimicrob Proteins. 2020;12(2):335-342. doi: 10.1007/s12602-019-09542-9.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 100 adults with functional constipation given strain Unique IS2 (2 billion CFU) or placebo daily for 4 weeks. Bowel movements increased more than with placebo (p < 0.001); 98% reached normal stool consistency versus 74% on placebo, with relief of incomplete evacuation, painful defecation and abdominal pain. Authors include employees of the maker, Unique Biotech.
- Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial. Benef Microbes. 2025;16(5):533-543. doi: 10.1163/18762891-bja00072.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 144 healthy adults with 3 to under 7 complete bowel movements a week, given strain Unique IS2 (2 billion CFU/day) or placebo for 4 weeks. The abstract reports a significant rise in bowel movement frequency, the primary outcome (p = 0.037), without stating it as a placebo comparison; stool consistency improved versus placebo (p = 0.018), mainly through fewer hard stools; GI symptoms, quality of life and gut microbiota did not change. The trial was sponsored by PepsiCo (ClinicalTrials.gov NCT05123664), and three co-authors are PepsiCo employees.
- Impact of Heyndrickxia (Bacillus) coagulans GBI-30, 6086 (BC30) probiotic on gastrointestinal function in healthy adults: a randomised controlled trial. Benef Microbes. 2025;17(1):29-46. doi: 10.1163/18762891-bja00084.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 111 healthy adults in China with functional GI complaints, given strain GBI-30, 6086 (BC30, 1 billion/day) or placebo for 4 weeks. Stools per week (p = 0.036), stool consistency (p < 0.001) and the share with constipation (p < 0.001) improved versus placebo; these are three of seven registered primary outcomes (ClinicalTrials.gov NCT06644001), which also include defecation effort and digestive symptom scores that the abstract does not report separately. The microbiome changed only slightly. Kerry sponsored the trial, and four of the seven authors work for Kerry companies.
- Probiotic Weizmannia coagulans MTCC 5856 as adjunct therapy in children's acute diarrhea-a randomized, double-blind, placebo-controlled study. Front Pediatr. 2023;11:1338126. doi: 10.3389/fped.2023.1338126.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 110 children aged 1 to 10 with acute diarrhea treated outside hospital, given strain MTCC 5856 (400 million spores) or placebo with oral rehydration and zinc for 5 days. Diarrhea lasted about 51 hours versus 63 hours on placebo (p = 0.011); daily frequency did not differ significantly. Most authors are Sami-Sabinsa employees.
- Randomised controlled clinical trial of Lactobacillus sporogenes (Bacillus coagulans), used as probiotic in clinical practice, on acute watery diarrhoea in children. Trop Med Int Health. 2011;16(5):555-61. doi: 10.1111/j.1365-3156.2011.02745.x.PubMedUsed to support: Randomized, double-blind, placebo-controlled hospital trial in 148 children aged 6 to 24 months with dehydrating acute watery diarrhea, given Lactobacillus sporogenes (Bacillus coagulans) tablets of unstated strain or placebo with oral rehydration. Recovery, duration, frequency and volume of diarrhea did not differ significantly between groups, including in rotavirus cases.
- Bacillus coagulans GBI-30, 6086 improves amino acid absorption from milk protein. Nutr Metab (Lond). 2020;17:93. doi: 10.1186/s12986-020-00515-2.PubMedUsed to support: Randomized, double-blind crossover in 30 healthy adults taking 25 g of milk protein concentrate daily for 2 weeks with or without strain GBI-30, 6086 (BC30). After the final dose, peak blood levels of total and essential amino acids and several individual amino acids were higher with BC30. Funded by an unrestricted grant from Kerry.
- Probiotic BC30 Improves Amino Acid Absorption from Plant Protein Concentrate in Older Women. Probiotics Antimicrob Proteins. 2024;16(1):125-137. doi: 10.1007/s12602-022-10028-4.PubMedUsed to support: Randomized, double-blind crossover trial in 30 healthy women (average age 58.5) taking 20 g of rice and pea protein daily for 14 days with or without 1 billion CFU of strain GBI-30, 6086 (BC30). Total and essential amino acid area under the curve and peak levels were significantly higher with BC30 (p = 0.035 to 0.050). Funded by an unrestricted grant from Kerry, which supplied both products.
- The effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study. Eur J Nutr. 2022;61(5):2673-2685. doi: 10.1007/s00394-022-02844-9.PubMedUsed to support: Double-blind, placebo-controlled trial in resistance-trained young men taking 20 g of whey protein daily with strain Unique IS-2 (2 billion CFU) or placebo for 60 days alongside a training program. Total plasma free amino acids rose 16.1%, and branched-chain amino acids were 33.1% higher than with placebo at 60 days; the authors also report a probiotic effect on leg-press 1RM and vertical jump power. Two authors are from Unique Biotech.
- Genome-based reclassification of Bacillus acidicola, Bacillus pervagus and the genera Heyndrickxia, Margalitia and Weizmannia. Int J Syst Evol Microbiol. 2023;73(7):005961. doi: 10.1099/ijsem.0.005961.PubMedUsed to support: Genome-based taxonomy study proposing to move the genus Weizmannia, which contains the former Bacillus coagulans, into the genus Heyndrickxia. Supports the statement that the species now appears in the literature as Weizmannia coagulans and Heyndrickxia coagulans.
- Probiotic Bacillus coagulans GBI-30, 6086 Improves Protein Absorption and Utilization. Probiotics Antimicrob Proteins. 2018;10(4):611-615. doi: 10.1007/s12602-017-9354-y.PubMedUsed to support: Review by researchers funded by or employed at Ganeden, the original maker of strain GBI-30, 6086. States that the strain withstands stomach acid, germinates in the intestine and aids carbohydrate and protein digestion. A maker-linked narrative review, not new trial data.
- Inactivated probiotic Bacillus coagulans GBI-30 induces complex immune activating, anti-inflammatory, and regenerative markers in vitro. J Inflamm Res. 2017;10:107-117. doi: 10.2147/JIR.S141660.PubMedUsed to support: Laboratory study in which inactivated cells of strain GBI-30, 6086 (sold as StaiMune) were added to human immune cells from healthy donors; the cells activated T, NK and NKT cells and raised several cytokines. No people took the ingredient. Three authors were employees of the sponsor, Ganeden. Supports the FAQ statement that StaiMune is an inactivated form of the same strain with its own, separate research.
- Probiotics: Usefulness and Safety. NCCIH (National Institutes of Health). 2019;Fact sheet, last updated August 2019. https://www.nccih.nih.gov/health/probiotics-what-you-need-to-know.SourceUsed to support: Not PubMed-indexed (US government fact sheet, read on the NCCIH site). States that the risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems, and that the FDA has warned that premature infants given probiotics are at risk of severe, potentially fatal infections.